MIA YANG CHEN, M.S.

**** ********* ** *** *, Indianapolis, IN 46143 317-***-**** adjdpw@r.postjobfree.com US Citizen

PROFESSIONAL SUMMARY

Experienced business partner and strategic leader with a demonstrated history of expertise in both pharmaceutical and academia. Skilled in communications, project management, coaching/mentoring/training, scientific writing, Good Publication Practices, presenting, project design, working in cross-functional, and multiple GxP environments (GLP, GDP, GCP, GRP). Looking to expand business acumen across different industries.

WORK HISTORY

Nov 2019 – Present Associate Consultant – Publication Planning

Global Scientific Communications (GSC) – Diabetes, Eli Lilly & Co. – Indianapolis, IN

Work with cross-functional, multidisciplinary teams to prepare clinical trials scientific disclosures (SD)/publications and communicates to business units on internal SD strategies/tactics

Provides input on SD strategy and tactics and manages/executes tactics based upon strategy

Manages implementation for multiple compound-specific, SD plans, including those from multiple large and high priority assets/compounds, and ensuring consistency within and across assets

Develops and maintains publications metrics/dashboard for assets

Maintains budgets for projects

Organizes content for SD strategy and operational meetings, including change controls, escalations, and project updates

Interacts with internal/external business partners and vendors about timelines and process

Ensures disclosures are aligned to appropriate venues and methods of disclosing study results in a manner that is compliant with PhRMA, ICMJE guidelines, and Eli Lilly policy

Identifies, evaluates, and resolves conflict

Ensures publications achieve balance between business needs, scientific integrity, and compliance with publication guidelines

Collaborates with Publication Leads and writers to develop/execute SD plan and complete disclosure deliverables

Functions as point of contact for SD plan tactics and Lilly disclosures at scientific congresses

Leading and providing clarification on local implementation of SOPs across teams and affiliates

Functions as subject matter expert for publications communication point for potential process improvements, industry guidelines pertaining to data dissemination, interactions with health care providers

Ensures consistency within own therapeutic area and across other therapeutic areas

2019 – Nov 2019 Consultant – Pubs Strategy & Execution Lead / Manager

Global Scientific Communications (GSC) – Oncology, Eli Lilly & Co. – Indianapolis, IN

Work with cross-functional, multidisciplinary teams to prepare clinical trials SD/publications

Leads development of scientific disclosure strategy for assets/portfolio, providing effective & novel publication strategies

Engages with customers, opinion leaders, patient advocacy groups, professional societies/medical associations, & publishers

Builds cross-functional relationships with development/medical affairs & other experts within Lilly. Collaborates & advises teams on publication strategy/planning/execution for launches

Functions independently as decision-maker on publication-related issues

Responsible for management/delivery of overall book of work for assigned areas

Develops & executes sourcing plans to ensure delivery of asset plan & priorities

Collaborates with functional leadership to ensure alignment of business planning/operations & develops alliances with therapeutic areas, phases of development, and geographies

Recruits/develops/retains strategic & operationally capable workforce skilled & knowledgeable in scientific communications

Effectively builds/manages organization that continuously meets the needs of changing portfolio

Develops staff who demonstrate expertise in drug development, therapeutic area, critical thinking, project management & cross-functional leadership

Provides mentoring/training/supervision & evaluates performance to direct reports/staff

Leads development of new and emerging capabilities

Functions as authority on SD strategy, planning and execution, industry standards/guidelines

Partners/designs/creates training on publication practices for audiences in/outside of GSC

Serves as a subject matter expert & represents publications on committees/task forces

In partnership with others, develops, implements, and updates Lilly publication policies, practices and tools and procedures that are compliant with industry guidelines

2018 – 2018 Senior Associate

Global Scientific Communications (GSC) – Oncology, Eli Lilly & Co. – Indianapolis, IN

Work with cross-functional, multidisciplinary teams to prepare clinical trials SD/publications

Plan, write (first-draft authoring), edit, review and coordinate disclosures

Effectively collect and evaluate data/information/input from multiple sources, functions, and regions to ensure authoring team alignment/understanding

Assist in building persuasive and scientific-based arguments that support the purpose of more complex and/or strategic documents

Ensure that key data, strategically aligned scientific narrative, elements and resource documents are included appropriately, accurately, balanced and supported by appropriate data

Exhibit flexibility in moving across multiple document types and compounds

Work with teams to ensure smooth and timely development of documents and escalate issues, as appropriate, to ensure document completion and to be able to influence or negotiate change of timelines and content

Provide oversight on individual deliverables, including timeline management, delivery of feedback and issue management by building and managing relationships with vendor/alliance partners

Possess overarching view of compound/therapeutic area/external environment with ability to participate effectively in the scientific data disclosure planning, clinical planning, and/or current awareness literature updates and reviews

Network different functions and regions to identify and contribute to process improvements, suggesting opportunities where appropriate

2014 – 2017 Senior Biologist

Diagnostic Experimental Pathology (DEP), Eli Lilly & Co. - Indianapolis, IN

Developed and characterized novel biomarker assays using techniques such as IHC/ISH for pre-clinical research and to support clinical trial assay development efforts

Served as expert on multiple techniques/equipment platforms

Supported Lilly’s NGR efforts by implementing the BaseScope assay in the DEP lab for direct application to “Trailblazer” projects that had portfolio impacts

Took lead and managed multiple high priority projects

Contributed to project design/protocol/technique/process/SOP development and improvement

2013 – 2014 Biologist

Advanced Testing Laboratory - Eli Lilly & Co. site, Indianapolis

Supported the histology group by processing, embedding, staining, and tracking human and mouse tissue/samples

Established and maintained human cancer cell lines to use for portfolio research projects

2006 – 2013 Research Technician (part-time)

Herman B Wells Center for Pediatric Research

Indiana University School of Medicine.

Dr. D. Wade Clapp, M.D., Physician-in-Chief for Riley Hospital for Children; Chairman and Richard L. Schreiner Professor, Pediatrics; Microbiology/Immunology and Biochemistry/Molecular Biology

Worked and was responsible for an independent project looking at how Kinase suppressor of Ras modulates mast cell function and its relations to inflammatory diseases and oncology related pathways (project design and execution)

Developed expertise in laboratory techniques, analysis, presentations, and publications

EDUCATION

2012 – 2013 Master of Science, Biology

Indiana University-Purdue University Indianapolis, Purdue School of Science (Indianapolis, IN), Master of Science Program, Pre-Professional

2008 – 2012 Bachelor of Science, Biology

Indiana University, College of Arts and Science (Bloomington, IN) – Dean’s List

Minors: Animal Behavior, East Asian Languages

MANAGING/MENTORING/LEADERSHIP

Helped coach and provide guidance to newly hired peers and colleagues with GSC processes

Presided and contributed as a member of the GSC Oncology social committee to promote team’s work/life balance and oversee teambuilding activities for the group

Invited and participated at 2018 Indianapolis Women’s Leadership Conference

Trained and mentored contractors (10+) at Eli Lilly for Experimental Pathology techniques and procedures

Coached new Eli Lilly employees on laboratory techniques

Participated in leadership for Test Menu support of immunohistochemistry and in situ hybridization

Presided as Hosting Chair and Co-Communication Chair for Chinese Culture Network (CCN) at Eli Lilly (2015)

CCN Communications Committee at Eli Lilly (2015 – Present)

PROFESSIONAL ACTIVITIES AND ACHIEVEMENTS

Publications:

1.Nasir A, Holzer TR, Chen M, Man MZ, Schade AE. Differential Expression of VEGFR2 Protein in Her-2 Positive Primary Human Breast Cancer: Potential relevance to anti-angiogenic therapies. Cancer Epidemiology, Biomarkers & Prevention. Cancer Cell International. 2017; 17:56.

2.Chen M, Burgin S, Staser K, He Y, Li X, Robinson M, Jiang L, Chan RJ, Ingram D, and Clapp DW. Kinase Suppressor of Ras (KSR1) modulates multiple Kit-ligand-dependent mast cell functions. Exp Hematol. 2011, 39(10): 969-76

3.Yang Z, Chen M, Sitarski SA, Saadatzadeh T, Yin F, Yu M, Yang F-C, and Chan RJ. Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (Ksr1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K. Leukemia Research. 2011, 35(7): 961-4

4.Chen S, Burgin S, McDaniel A, Li X, Yuan J, Chen M, Khalaf W, Clapp DW, and Yang F-C. Nf1-/- Schwann cell conditioned medium modulates mast cell degranulation by C-Kit mediated hyperactivation of PI-3 kinase. Am J Pathol. 2010, 177(6):3125-32

Abstracts:

1.Nasir A, Falcon B, Wang D, Holzer T, Nonte E, Chen M, Fulford A, Carter J, Douglass L, Pytowski B, Bell-McGuinn KM, Walgren R, Schade A, Chaudhry A. Vascular and Tumor Cell Expression of VEGFR2 and Molecular Subtyping: An Innovative Biomarker Approach in Bladder Cancer. Currently in submission to ASCO-GU 2018 (Clinical).

2.Nasir A, Wang D, Chen M, Liu J, Bowden E, Das Mayukh, Malafa MP, Walgren RA, Schade AE, Coppola D, Chaudhry A. Molecular Heterogeneity is the Dominant Theme in Protein-based Classification of GC/GEJ Adenocarcinoma. AACR 2018.

3.Nasir A, Wang D, Chen M, Liu J, Bowden E, Das Mayukh, Malafa MP, Walgren RA, Schade AE, Coppola D, Chaudhry A. Protein/RNA-based molecular Subtyping of Gastric and GEJ Adenocarcinoma Further Refines the Original molecular Characterization by TCGA. AACR 2018.

4.LeBlanc A, Oakley III, Gerard, Lowery C, Mendoza A, Ren L, Holzer T, Credille K, Winings C, Estelle A, Chen M, Finnegan P, Blosser W, Schade A, Melemed S, Stancato L. The anti-platelet-derived growth factor receptor α antibody olaratumab (Lartruvo) increases overall survival in metastatic mouse models of human osteosarcoma. AACR 2017

5.Nasir A, Holzer TR, Chen M, Man M, Benjamin L, Melemed AS, Schade AE. Differential Expression of VEGFR2 Protein in Her2 Positive Primary Human Breast Cancer: Potential Relevance to Newer Anti-Angiogenic Therapies. AACR 2015 poster.

Awards and Scientific Presentations:

1.Nasir A, Chen M, Holzer TR, Man M, Benjamin L, Melemed AS, Schade AE. Differential Expression of VEGFR2 Protein in Her2 Positive Primary Human Breast Cancer: Potential Relevance to Newer Anti-Angiogenic Therapies. American Association of Cancer Research Annual Meeting, Philadelphia, 2015.

2.Achievement Award, 49th Annual Meeting of the American Society of Hematology, Atlanta, 2007

3.Presenter, 48th Annual Midwest Society for Pediatric Research, Indianapolis, IN, 2007

PROFESSIONAL SOCIETIES

2020 – Present: Medical Affairs Professional Society (MAPS)

2013 – Present: Women in Lilly Leadership (WILL)

LANGUAGES

English (Fluent)

Chinese (Fluent)

Contact this candidate